Experience

A biochemist by training Mike worked for 20 years in GSK (Glaxo, Glaxo Wellcome) mostly in the natural product area. In 2003 he cofounded Novacta Biosystems Limited where as CSO he led the development of a semi-synthetic lantibiotic NVB302 into the clinic for C. difficile infection. From 2012 - 2017 as CEO of Cantab Anti-infectives Mike led the company through the successful development of improved polymyxin analogues now progressing with Spero Therapeutics Inc. Mike brings a wealth of experience in antibacterials as well as in all aspects of running a small company.

Opportunity evaluation/assessment

Business start up/Business plan development

Project management

Grant applications 

Programme/portfolio review